NCT03653533 (AAHPI) is a NA clinical trial of MiniMed™ 640G in Type I Diabetes, sponsored by ARAIR Assistance.

Who is sponsoring NCT03653533?

NCT03653533 is sponsored by ARAIR Assistance.

What drugs are being tested in NCT03653533?

Interventions in NCT03653533: MiniMed™ 640G, Captor CGM Enlite®, SmartGuard®.

What condition does NCT03653533 study?

NCT03653533 studies Type I Diabetes.

Is NCT03653533 still recruiting?

NCT03653533 is currently terminated. Last updated 10 July 2020.

Last reviewed 2020-07-10 · How we verify

NCT03653533: AAHPI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump

Terminated NA Last updated 10 July 2020

What this trial tests

NA trial testing MiniMed™ 640G in Type I Diabetes in 8 participants. Terminated before completion.

Timeline

7 January 2019

Primary endpoint
18 October 2019

18 October 2019

Quick facts

Lead sponsor	ARAIR Assistance
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	7 January 2019
Primary completion	18 October 2019
Estimated completion	18 October 2019
Sites	1 location across France

Drugs / interventions tested

MiniMed™ 640G
Captor CGM Enlite®
SmartGuard®

Conditions studied

Type I Diabetes — all drugs for Type I Diabetes →

Sponsor

ARAIR Assistance

Who can join

18 and older, any sex, with Type I Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the apparition of hypoglycaemia in type I diabetic patients between 2 phases: the one without the use of SmartGuard® function and the one with the use of SmartGuard® function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type I Diabetes

Currently open trials in the same condition.

NCT06964087 — Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03653533 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ARAIR Assistance
Last refreshed: 10 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing